Lagevrio is an antiviral medication used to treat mild-to-moderate COVID-19 in adults who are at high risk of becoming seriously ill. It contains the active ingredient molnupiravir and is taken as a pill at home, making it one of a small number of oral treatments available for COVID-19. The FDA authorized it for emergency use specifically when other preferred treatments aren’t accessible or appropriate for the patient.
Who Lagevrio Is Designed For
Lagevrio targets a specific group: adults 18 and older who have tested positive for COVID-19, have mild-to-moderate symptoms, and carry risk factors that make them more likely to end up in the hospital or die from the infection. It is not a treatment for everyone who catches COVID-19. It’s reserved for people whose underlying health puts them in danger of the disease getting worse.
The clinical trial that led to its authorization enrolled patients with at least one of the following risk factors: age over 60, diabetes, obesity (BMI of 30 or higher), chronic kidney disease, serious heart conditions, chronic obstructive pulmonary disease, or active cancer. These conditions track closely with the CDC’s broader list of factors that increase the risk of severe COVID-19.
Lagevrio is not authorized for patients under 18. It is also not meant to be started once someone is already sick enough to be hospitalized. The drug is specifically for outpatient use, catching the virus early before it progresses.
How It Fits Among COVID-19 Treatments
Lagevrio is not the first-choice antiviral for COVID-19. Current treatment guidelines from the Infectious Diseases Society of America place it behind two other options. The preferred treatment is Paxlovid (nirmatrelvir/ritonavir), an oral antiviral with higher efficacy. If Paxlovid isn’t suitable, a short course of intravenous remdesivir is the next recommendation. Lagevrio comes into play when neither of those options works for a given patient.
The most common reason Lagevrio gets used instead of Paxlovid is drug interactions. Paxlovid interacts with a long list of commonly prescribed medications, including certain heart drugs, blood thinners, cholesterol-lowering statins, and immunosuppressants. Lagevrio, by contrast, has essentially no significant drug interactions. For patients who take multiple medications daily, particularly older adults managing several chronic conditions, Lagevrio can be the safer practical choice even if it’s not the most effective antiviral on paper.
How Well It Works
In the MOVe-OUT clinical trial, Lagevrio cut the risk of hospitalization or death by roughly 50% compared to placebo in high-risk patients with mild-to-moderate COVID-19. By day 29, 7.3% of patients who received Lagevrio had been hospitalized or died, compared to 14.1% in the placebo group. These results came from a population that was unvaccinated at the time of the trial, and current guidelines note that the real-world benefit may be less certain in a population with widespread vaccination and prior infection.
That uncertainty is part of why guidelines describe the evidence for Lagevrio as “low certainty” and recommend it conditionally, only when better options aren’t available.
Dosage and Timing
The treatment course is straightforward: four 200 mg capsules (800 mg total) taken twice a day for five days. You can take them with or without food. The full course is 40 capsules over five days, and the treatment should not be extended beyond that window.
Timing matters. Lagevrio must be started within five days of when your symptoms first appeared. The sooner you begin, the better. This means getting tested quickly and having a prescription in hand early in the course of illness. Waiting too long after symptom onset reduces the drug’s usefulness.
How Lagevrio Works in the Body
Lagevrio works differently from Paxlovid. Instead of blocking the virus from assembling new copies of itself, molnupiravir gets incorporated into the virus’s genetic material as it replicates. Once inside, it introduces errors into the viral code, essentially scrambling the instructions the virus needs to make functional copies. After enough errors accumulate, the virus can no longer reproduce effectively.
This mechanism is effective, but it’s also the source of the drug’s main safety concern. Because it works by causing mutations in genetic material, there are theoretical worries about whether it could affect human DNA as well. Animal studies have raised enough concern that the drug carries specific restrictions around pregnancy and reproduction.
Pregnancy and Reproductive Safety
Lagevrio is not recommended during pregnancy. Animal reproduction studies found it may cause fetal harm. If you are of childbearing potential, you should use effective contraception during treatment and for four days after the final dose. This applies to both the direct risk during pregnancy and the broader concern about the drug’s mutagenic properties.
Guidelines specifically flag this issue, recommending that prescribers clearly communicate the potential effects on fertility when discussing Lagevrio with patients of childbearing potential.
Side Effects
Lagevrio is generally well tolerated over its short five-day course. The most commonly reported side effects are gastrointestinal: diarrhea and nausea. Some patients also experience dizziness. These effects tend to be mild and manageable, and serious adverse reactions during clinical trials were uncommon. The short treatment duration helps limit side effect burden compared to medications taken over weeks or months.
When Lagevrio Makes Sense
In practice, Lagevrio fills a specific niche. It’s the option for high-risk adults who can’t take Paxlovid because of drug interactions, who can’t access intravenous remdesivir, or who have another clinical reason that rules out the preferred treatments. If you’re over 60 or manage conditions like diabetes, kidney disease, or heart problems, and you test positive for COVID-19 with symptoms, it’s worth asking your doctor early whether any antiviral treatment is appropriate for you. The five-day clock from symptom onset is tight, and delays in seeking treatment can close the window entirely.